Belgium · Delayed Price · Currency is EUR Materialise NV Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 6.8% in Q4 2025, with strong medical segment growth offsetting manufacturing declines. 2026 guidance anticipates continued double-digit medical growth, stable software, and ongoing manufacturing headwinds, with adjusted EBIT expected at EUR 10–12 million.
-
Q3 2025 saw strong double-digit growth in the medical segment, offsetting declines in software and manufacturing due to macroeconomic headwinds. Gross margin remained robust at 56.8%, and guidance for FY 2025 was maintained, with confidence in future growth as market conditions improve.
-
Q2 2025 saw strong double-digit growth in the medical segment, offset by declines in software and manufacturing due to macroeconomic and FX headwinds. Revenue guidance for the year was slightly reduced, but profitability guidance was maintained, with cost control and strategic investments supporting resilience.
-
Revenue grew 4% year-over-year in Q1 2025, led by strong medical segment growth, while software and manufacturing faced headwinds. Net loss was EUR 0.5 million due to FX impacts, but cash flow remained strong. Full-year guidance is maintained despite expected Q2 challenges.
Fiscal Year 2024
-
2024 saw 4% revenue growth and stable adjusted EBIT despite macroeconomic headwinds, with strong performance in medical and aerospace offset by weakness in manufacturing and automotive. 2025 guidance anticipates continued growth in medical and software, but ongoing challenges in manufacturing due to European market conditions.
-
Q3 2024 saw revenue rise 14% to €68.7M, with strong growth in medical and all segments profitable. Guidance for full-year revenue and EBIT is maintained, while investments in ACTech and software partnerships support future growth.
-
Q2 2024 saw record revenue of €68.8M (+6.2% YoY), strong growth in all segments, and a net profit of €3.9M. Medical led with 13% revenue growth, while software recurring revenue surpassed 70%. Full-year guidance is maintained despite integration costs from the FEops acquisition.